Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

R2D2 trial: deprescribing anticholinergics may shield aging brains

NCT ID NCT04270474

Prevention Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests whether a pharmacist-led program to stop certain medications (anticholinergics) can lower dementia risk in older adults. 344 participants aged 65+ who take these drugs will be followed for 2 years, comparing cognitive changes and quality of life between those who deprescribe and those who continue usual care. The goal is to see if reducing these medications improves thinking and memory.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deprescribing of anticholinergic medications
What this could lead to
If successful, this could show that stopping certain medications reduces dementia risk and improves cognitive function in older adults.
What could go wrong
This is a relatively small, early-stage trial (344 participants) focused on a specific medication class. Results may not apply to all older adults, and deprescribing may not significantly impact cognition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

344 people

The number who actually took part.

Started

Jul 2020

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Participants: * Age 65 and older; * At least one office visit to their primary care physician within the previous 12 months; * Use of a target anticholinergic medication within the last two weeks OR medical record evidence of exposure to target anticholinergic medications at or above a cognitive risk threshold in the prior 12 months * Able to communicate in English; * Access to a telephone Exclusion Criteria for Participants: * Permanent resident of an extended care facility (nursing home) * Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder defined by International Classification of Diseases (ICD) version 9/10 codes * Diagnosis of Alzheimer's Disease or Related Dementia as determined by (a), (b), or (c) below: 1. ICD-9/10 codes, or 2. Current use of a medication for Alzheimer's Disease or a Related Dementia, or 3. A pattern of responses to the Functional Activities Questionnaire (FAQ) that indicate dementia (i.e., ≥ 3 FAQ items are scored at "requires assistance," or if ≥ 1 FAQ item is scored at "dependent").

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease, late onset are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Alzheimer disease 2 dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease, late onset Dementia

Contacts and locations

Locations

  • Community Health Network Foundation, Inc.

    Indianapolis, Indiana, 46256, United States

  • Indiana University Health

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.